Acquisition taps into the unknown treasures of the sea
Croda are using marine microbial biodiversity to discover novel actives and materials for applications across all its market sectors.
Screening for new marine-derived functional ingredients and bringing new patented products to the market.
Earlier this year, Croda, who create, make and sell speciality chemicals for some of the biggest, most successful brands in the world, acquired Nautilus, a marine biotechnology company based at the University of Prince Edward Island, Canada. So, what's in it for Croda?
Why Marine Biotechnology?
Much of the biodiversity on land has been mapped, yet this is not the case for the ocean and freshwater ecosystems that represent more than 70% of the Earth’s surface. Within these unmapped ecosystems, the potential for discovery of biological resources capable of generating a wide variety of materials is huge. Oceanic environments experience the greatest extremes of temperature, light and pressure encountered by life. Adaptation to these harsh environments has led to rich marine bio and genetic diversity with potential biotechnological applications related to drug discovery, environmental remediation and industrial processes.
To date, most marine biotechnology developments have been related to drug discovery. Plans for its use in other industries, however, are also being developed, including materials for cosmetic applications. Studies of extremophiles, micro-organisms found in hostile environments that have developed specific survival mechanisms, have led to the development of novel functional ingredients for the cosmetics industry. Croda already offers a skin care ingredient based on a powerful cocktail of UV and temperature-stable enzymes developed from bacteria that live in hot and highly oxidative deep-sea environments.
Successful Collaboration
Croda and Nautilus already have a proven history of successful collaboration, having worked closely together for the past 6 years developing novel materials for applications in skin care, hair care and crop care. Their collaboration has resulted in the discovery of several novel functional materials that are continuing to be developed for specific applications, such as anti-microbial.
Nautilus will be established as a Croda Centre of Innovation for Marine Biotechnology at their existing base at the University of Prince Edward Island, continuing to also work with the University, where an extensive library of dereplicated marine microbes collected and acquired from various regions of the world can be accessed. The acquisition will allow Croda to screen for new marine-derived functional materials for applications across all its interests and bring new patented products to the market.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance